参考文献/References:
[1] Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis[J]. Lancet, 2016, 387(10038): 2641-2654.
[2] 中国系统性轻链型淀粉样变性协作组.国家肾脏疾病临床医学研究中心,国家血液系统疾病临床医学研究中心.系统性轻链型淀粉样变性诊断和治疗指南(2021年修订)[J].中华医学杂志,2021,101(22):1646-1656.
[3] 刘颖娴,廉慧,李剑,等.心脏淀粉样变性合并脑梗死的单中心诊疗经验[J].中国介入心脏病学杂志,2019,27(10):567-573.
[4] Kyle RA, Linos A, Beard CM, et al. O'fallon WM,kurland LT[J]. Incidence and natural history of primary systemic amyloidosis in Olmsted County,Minnesota,1950 through 1989. Blood, 1992, 79(7): 1817-1822.
[5] Hemminki K, Li X, Försti A, et al. Incidence and survival in non-hereditary amyloidosis in Sweden[J]. BMC Public Health, 2012, 12: 974.
[6] Pinney JH, Smith CJ, Taube JB, et al. Systemic amyloidosis in England: an epidemiological study[J]. Br J Haematol, 2013, 161(4): 525-532.
[7] Huang XH, Liu ZH. The clinical presentation and management of systemic Light-Chain amyloidosis in China[J]. Kidney Dis(Basel), 2016, 2(1): 1-9.
[8] Mubarak M. The renal histopathological spectrum of patients with nephrotic syndrome: an analysis of 1523 patients in a single Chinese centre[J]. Nephrol Dial Transplant, 2011, 26(10): 3419; author reply 3419-20.
[9] Merlini G, Dispenzieri A, Sanchorawala V, et al. Systemic immunoglobulin light chain amyloidosis[J]. Nat Rev Dis Primers, 2018, 4(1): 39.
[10] Vaxman I, Gertz M. When to suspect a diagnosis of amyloidosis[J]. Acta Haematol, 2020, 143(4): 304-311.
[11] Lousada I, Comenzo RL, Landau H, et al. Light chain amyloidosis: patient experience survey from the amyloidosis research consortium[J]. Adv Ther, 2015, 32(10): 920-928.
[12] Merlini G, Stone MJ. Dangerous small B-cell clones[J]. Blood, 2006, 108(8): 2520-2530.
[13] Gj M, Kelly JW. The kinetic stability of a Full-Length antibody light chain dimer determines whether endoproteolysis can release amyloidogenic variable domains[J]. J Mol Biol, 2016, 428(21): 4280-4297.
[14] Bianchi G, Zhang Y, Comenzo RL. AL amyloidosis: current chemotherapy and immune therapy treatment strategies: JACC: CardioOncology State-of-the-Art review[J]. JACC CardioOncol, 2021, 3(4): 467-487.
[15] Tennent GA, Lovat LB, Pepys MB. Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis[J]. Proc Natl Acad Sci USA, 1995, 92(10): 4299-4303.
[16] Marin-Argany M, Lin Y, Misra P, et al. Cell damage in light chain amyloidosis: fibril internalization, toxicity and cell-mediated seeding[J]. J Biol Chem, 2016, 291(38): 19813-19825.
[17] Qian M, Qin L, Shen K, et al. Light-Chain amyloidosis with peripheral neuropathy as an initial presentation[J]. Front Neurol, 2021, 12: 707134.
[18] Namiranian D, Geisler S. Neuromuscular Complications of Systemic Amyloidosis[J]. Am J 2022, 135( Suppl 1): S13-S19.
[19] Kaku M, Berk JL. Neuropathy associated with systemic amyloidosis[J]. Semin Neurol, 2019, 39(5): 578-588.
[20] Rajkumar SV, Gertz M, Kyle RA. Prognosis of patients with primary systemic amyloidosis who present with dominant neuropathy[J]. Am J Med, 1998, 104(3): 232-237.
[21] Koike H, Mouri N, Fukami Y, et al. Two distinct mechanisms of neuropathy in immunoglobulin light chain(AL)amyloidosis[J]. J Neurol Sci, 421: 117305.
[22] 肖一,张灵语,欧汝威,等.神经丝蛋白轻链与帕金森综合征相关研究进展[J].中华神经科杂志,2021,54(8):843-847.
[23] Louwsma J, Brunger AF, Bijzet J, et al. Neurofilament light chain,a biomarker for polyneuropathy in systemic amyloidosis[J]. Amyloid, 2021, 28(1): 50-55.
[24] Muchtar E, Derudas D, Mauermann M, et al. Systemic immunoglobulin light chain Amyloidosis-Associated myopathy: presentation, diagnostic pitfalls, and outcome[J]. Mayo Clinic Proceedings, 2016, 91(10): 1354-1361.
[25] Hull KM, Griffith L, Kuncl RW, et al. A deceptive case of amyloid myopathy: clinical and magnetic resonance imaging features[J]. Arthritis Rheum, 2001, 44(8): 1954-1958.
[26] Friedman Y, Paul JT, Turley J, et al. Axial myopathy due to primary amyloidosis[J]. Muscle Nerve, 2007, 36(4): 542-546.
[27] Yoshida H, Kim K, Harada K. A case of amyloid myopathy diagnosed during the treatment of myopathy associated with anti-signal recognition particle antibodies[J]. Rinsho Shinkeigaku, 2017, 57(4): 168-173.
[28] Ono E, Ishii A, Higashi Y, et al. Monoclonal gammopathy of renal significance(MGRS)-related AL amyloidosis complicated by amyloid myopathy: a case report[J]. BMC Nephrol, 2021, 22(1): 74.
[29] 张伟,蒋丽君,马燕萍,等.以淀粉样肌病为主要表现的系统性轻链型淀粉样变性一例[J].中华血液学杂志,2021,42(9):768-768.
[30] Draghici M, Jercan A, Badelita SN, et al. Muscle involvement with pseudohypertrophy in systemic light chain amyloidosis: Case report[J]. Medicine(Baltimore), 2021, 100(51): e28267.
[31] Moshe LO, Banks G, Medvedova E, et al. Coexisting sporadic late onset nemaline myopathy and AL amyloid myopathy - incidental or related?[J]. Neuromuscul Disord, 2022, 32(6): 533-538.
[32] Zubkov AY, Rabinstein AA, Dispenzieri A, et al. Primary systemic amyloidosis with ischemic stroke as a presenting complication. Neurology[J]. 2007, 69(11): 1136-41.
[33] Yusuf SW, Solhpour A, Banchs J, et al. Cardiac amyloidosis[J]. Expert Rev Cardiovasc Ther, 2014, 12(2): 265-277.
[34] Shah KB, Inoue Y, Mehra MR. Amyloidosis and the heart: a comprehensive review[J]. Arch Intern Med, 2006, 166(17): 1805-1813.
[35] Roberts WC, Waller BF. Cardiac amyloidosis causing cardiac dysfunction: analysis of 54 necropsy patients[J]. Am J Cardiol, 1983, 52(1): 137-146.
[36] Hausfater P, Costedoat-Chalumeau N, Amoura Z, et al.AL cardiac amyloidosis and arterial thromboembolic events[J]. Scand J Rheumatol 2005, 34(4): 315-319.
[37] Feng D, Edwards WD, Oh JK, et al. Intracardiac thrombosis and embolism in patients with cardiac amyloidosis[J]. Circulation, 2007, 116(21): 2420-2426.
[38] Sanchis K, Cariou E, Colombat M, et al. Atrial fibrillation and subtype of atrial fibrillation in cardiac amyloidosis: clinical and echocardiographic features, impact on mortality[J]. Amyloid, 2019, 26(3): 128-138.
[39] Nicol M, Siguret V, Vergaro G, et al. Thromboembolism and bleeding in systemic amyloidosis: a review[J]. ESC Heart Fail, 2022, 9(1): 11-20.
[40] Sucker C HG, bleeding:pathophysiology. Diagnosis,and therapy[J]. Am J Kidney Dis, 2006, 47(6): 947-955.
[41] Zhang XD, Liu YX, Yan XW, et al. Cerebral embolism secondary to cardiac amyloidosis: A case report and literature review[J]. Exp Ther Med, 2017, 14(6): 6077-6083.
[42] Shinoda N, Hirashiki A, Ohshima S, et al. Cerebral embolism due to atrial myopathy in a cardiac amyloidosis patient diagnosed by cardiac magnetic resonance imaging[J]. J Cardiol Cases, 2013, 7(3): e78-e81.
[43] 刘扬,黄湘华,段文冰,等.达雷妥尤单抗治疗原发系统性轻链型淀粉样变:多中心回顾性分析[J].中华内科杂志,2021,60(11):987-992.
[44] Palladini G, Kastritis E, Maurer MS, et al. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA[J]. Blood, 2020, 136(1): 71-80.
[45] 任贵生,郭锦洲,赵亮,等.达雷妥尤单抗治疗复发难治性系统性轻链型淀粉样变性的疗效和安全性观察[J].肾脏病与透析肾移植杂志,2021,30(3):205-210.